Delcath Systems, Inc.
NASDAQ:DCTH
Overview | Financials
Company Name | Delcath Systems, Inc. |
Symbol | DCTH |
Currency | USD |
Price | 11.34 |
Market Cap | 362,582,892 |
Dividend Yield | 0% |
52-week-range | 3.7 - 13.301 |
Industry | Medical Devices |
Sector | Healthcare |
CEO | Mr. Gerard J. Michel MBA, MS |
Website | https://www.delcath.com |
An error occurred while fetching data.
About Delcath Systems, Inc.
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD